Expertise in
6
conditions

Dr. Princy N. Kumar

Infectious Disease
Mgmc LLC
3800 Reservoir Rd Nw, 
Washington, DC 
Accepting New Patients
Offers Telehealth
Expertise in
6
conditions
Mgmc LLC
3800 Reservoir Rd Nw, 
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Princy Kumar is an Infectious Disease provider in Washington, Washington, D.c.. Dr. Kumar is highly rated in 6 conditions, according to our data. Her top areas of expertise are HIV/AIDS, COVID-19, Multisystem Inflammatory Syndrome in Children (MIS-C), Thrombectomy, and Endoscopy. Dr. Kumar is currently accepting new patients.

Her clinical research consists of co-authoring 105 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Infectious Disease
Licenses
Internal Medicine in DC
Hospital Affiliations
Medstar Georgetown University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

MGMC LLC
3800 Reservoir Rd Nw, Washington, DC 20007
Other Locations
MEDSTAR MEDICAL GROUP II LLC
1145 19th St Nw, 311 Mmg At 19th Street Nw, Washington, DC 20036

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-1 Infected Adults Who Are Virologically Suppressed and Participated in Study LAI116482
A Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-1 Infected Adults Who Are Virologically Suppressed and Participated in Study LAI116482
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Long-acting cabotegravir, Long-acting rilpivirine, Rilpivirine, Dolutegravir
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Drug
Study Drug: TJ003234
Study Phase: Phase 2/Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1
A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1
Enrollment Status: Completed
Publish Date: March 11, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

105 Total Publications

Angiogenic CD8 T cells from PWH induce Granzymes-dependent PAR1 activation promoting endothelial inflammation.
Angiogenic CD8 T cells from PWH induce Granzymes-dependent PAR1 activation promoting endothelial inflammation.
Journal: bioRxiv : the preprint server for biology
Published: October 01, 2025
Similar Doctors
Naomi E. Aronson
Expertise in
1
conditions
Dr. Naomi E. Aronson
Infectious Disease
Expertise in
1
conditions
Dr. Naomi E. Aronson
Infectious Disease
Walter Reed Army Medical Center, 6900 Georgia Ave Nw, 
Washington, DC 
 (5.1 miles away)
202-782-1663
Languages Spoken:
English

Naomi Aronson is an Infectious Disease provider in Washington, Washington, D.c.. Dr. Aronson is highly rated in 1 condition, according to our data. Her top area of expertise is Leishmaniasis.

Expertise in
7
conditions
Dr. Amy D. Klion
Infectious Disease
Expertise in
7
conditions
Dr. Amy D. Klion
Infectious Disease
9000 Rockville Pike, Nih, 
Bethesda, MD 
 (6.4 miles away)
301-435-8903
Languages Spoken:
English

Amy Klion is an Infectious Disease provider in Bethesda, Maryland. Dr. Klion is highly rated in 7 conditions, according to our data. Her top areas of expertise are Loiasis, Spirurida Infections, Secernentea Infections, Helminthiasis, and Tissue Biopsy.

Expertise in
2
conditions
Dr. Christian F. Ockenhouse
Infectious Disease
Expertise in
2
conditions
Dr. Christian F. Ockenhouse
Infectious Disease
6900 Georgia Ave Nw, Wramc Bldg 2 Department Of Medicine, 
Washington, DC 
 (5.1 miles away)
301-319-9473
Languages Spoken:
English

Christian Ockenhouse is an Infectious Disease provider in Washington, Washington, D.c.. Dr. Ockenhouse is highly rated in 2 conditions, according to our data. His top areas of expertise are Malaria and Sepsis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kumar's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile